Yin, Xiu-Feng <br/><br/>
Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.  [electronic resource] 

 -  Leukemia research  Oct 2014 
 - 1191-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-5835 
<br/><br/><label>Standard No.: </label>10.1016/j.leukres.2014.07.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Benzamides--therapeutic use<br/>Child<br/>Female<br/>Fusion Proteins, bcr-abl--genetics<br/>Humans<br/>Imatinib Mesylate<br/>Kaplan-Meier Estimate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Piperazines--therapeutic use<br/>Proportional Hazards Models<br/>Pyrimidines--therapeutic use<br/>Retrospective Studies<br/>Treatment Outcome<br/>Young Adult